Clinical Trials
Our goal is to help find the best treatment available whenever a treatment decision is needed. Often times, there may be a standard of care treatment that is appropriate for a specific situation. However, sometimes the current standard of care works for awhile but then stops working. For recurrent or refractory ovarian cancer, sometimes there is not a standard of care option. At these times, participation in a clinical trial may be the best available option. To be eligible for clinical trials, timing is everything. If treatment is begun without considering trials, the patient may later be ineligible. Please contact us so all options can be explored. The more women that take part in clinical trials for ovarian cancer, the faster we can find better treatments for everyone. Contact us at info@clearityfoundation.org.
Highlighted trials are listed below and a complete list of all ovarian cancer clinical trials can be found at http://www.clinicaltrials.gov/ct2/results?term=ovarian+cancer. For a Glossary of drug names, click here
Phase 3 Trials
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
PURPOSE: This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.
For more information: http://www.far-trials.com/
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II or Stage III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
PURPOSE: This randomized phase III trial is studying bevacizumab and intravenous chemotherapy to see how well they work compared with bevacizumab and intraperitoneal chemotherapy in treating patients with stage II or stage III ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma - Ovarian Cancer
PURPOSE: This is a placebo-controlled, randomized, multicenter Phase III study evaluating the safety and efficacy of bevacizumab, administered in combination with carboplatin with gemcitabine in women with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.
Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients with Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube - Ovarian Cancer
PURPOSE: This randomized phase III trial is studying giving carboplatin and paclitaxel together with or without bevacizumab after surgery to see how well it works in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer.
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
PURPOSE: This randomized phase III trial is studying carboplatin, paclitaxel, and bevacizumab to see how well they work compared with carboplatin and paclitaxel alone in treating patients with newly diagnosed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.
Phase 2 Trials
Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer - Ovarian Cancer
PURPOSE: The purpose of this study is to determine if the combination of Abraxane and Carboplatin together will improve the chances of controlling recurrent ovarian/fallopian tube/peritoneal cancer.
AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
PURPOSE: This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be conducted in the United States and Spain. Part 1 is a dose escalation segment to identify a dose of AMG 655 in combination with AMG 479 that is safe and tolerable. Part 2 will evaluate the safety and estimate the efficacy of AMG 655 at the dose selected in Part 1 in combination with AMG 479 for the treatment of patients with advanced NSCLC (non-squamous histology; squamous histology), CRC, pancreatic cancer, ovarian cancer, and sarcoma.
Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer
PURPOSE: This project is a pilot, phase II, open-label, single-center, non-comparative clinical study evaluating the antitumor efficacy and tolerability of exemestane in treating adult post-menopausal women with recurrent or refractory, stage II-IV, epithelial ovarian cancer.
Assessment of Efficacy of AZD2281 in Platinum Sensitive Serous Ovarian Cancer
PURPOSE: The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy.
Avastin and Erlotinib as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer, and Papillary Serous Mullerian Tumors
PURPOSE: The purpose of this research study is to evaluate how patients with newly diagnosed advanced ovarian, fallopian tube, primary peritoneal or papillary serous Mullerian tumor respond to Avastin and erlotinib, or Avastin alone over 1 year. These drugs have been used in the treatment of other types of cancers and information from those studies suggests that these agents may help to treat the cancers studied here.
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
PURPOUS: The purpose of this study is to evaluate how the participant's disease (ovarian, serous or fallopian tube cancer) responds to additional treatment with Avastin (bevacizumab). Participant's have already received Avastin as part of maintenance therapy for their cancer. Maintenance therapy is a medical therapy that is given to people to prevent a relapse. However, cancer may return after maintenance therapy. This research study hopes to determine whether additional treatment with Avastin will be effective in treating the participant's cancer.
Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer
PURPOSE: The Primary Objectives of the study are 1. To determine acceptable dosages of valproic acid and carboplatin in a regimen of sequential azacitidine and valproic acid plus carboplatin in the treatment of patients with advanced solid tumor during the phase 1 part. 2. To assess objective response rates in platinum resistant epithelial ovarian cancer patients treated with sequential azacitidine and valproic acid plus carboplatin during the phase 2 part. 3. To determine whether DNA methylation, and histone H3 and H4 acetylation of tumor tissue and peripheral blood monocytes are able to predict objective responses.
AZD6244 in Treating Woman with Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
PURPOSE: This phase II trial is studying the side effects and how well AZD6244 works in treating patients with recurrent low-grade ovarian cancer.
Bevacizumab and Docetaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer - Ovarian Cancer
PURPOSE: This phase II trial is studying how well giving bevacizumab together with docetaxel works in treating patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
PURPOSE: Comparison of Nexavar with a placebo as maintenance therapy for patients with advanced Ovarian or primary Peritoneal cancers in complete remission following surgery and one regimen of chemotherapy.
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
PURPOSE: This randomized phase II trial is studying how well giving cyclophosphamide together with celecoxib works compared to cyclophosphamide alone in treating patients with recurrent or persistent ovarian epithelial, fallopian tube, or primary peritoneal cancer.
Efficacy and Safety and Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
PURPOSE: The purpose of this study is to determine the efficacy and safety of using Doxil and Avastin on ovarian cancer patients who are resistant to or have relapsed from platinum-based therapy.
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
PURPOSE: This research is being done to find out if paclitaxel works better when given together with an experimental drug called MORAb-003(farletuzumab) or alone in patients with platinum-resistant or refractory relapsed ovarian cancer
Efficacy Study of Gleevec and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin
PURPOSE: This study is designed to determine whether the combination treatment of Paclitaxel and Gleevec on recurrent ovarian cancer patients or other cancers of mullerian origin will generate better clinical response than Paclitaxel alone.
Erlotinib and Bevacizumab in Treating Patients With Relapsed or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
PURPOSE: This phase II trial is studying the side effects and how well giving erlotinib together with bevacizumab works in treating patients with relapsed or refractory ovarian epithelial cancer or primary peritoneal cancer.
For more information: http://www.far-trials.com/
Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer
PURPOSE: This study will evaluate the efficacy and tolerability of the combination of Gleevec and Gemzar in patients with ovarian cancer, who have progressed after receiving at least one prior chemotherapy treatment. Gleevec is an oral chemotherapy drug used is this study and Gemzar is an IV chemotherapy drug used. Participation in the treatment portion of the study will continue as long as the patient's tumors shrink or remain stable and as long as the patient is able to tolerate the study drug. The follow-up portion of the study will last for 5 years.
MLN8237 for Treatment of Patients With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
PURPOSE: This is an open-label, multicenter, single-arm, phase 2 study of MLN8237 in the treatment of patients with platinum-refractory or platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinomas.
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
PURPOSE: This trial will compare the efficacy and toxicity of standard first-line chemotherapy alone vs. standard chemotherapy + sorafenib in patients with stage III/IV ovarian cancer following cytoreductive surgery. Patients with residual large volume disease and/or bowel involvement will be excluded, to minimize the risk of bowel perforation.
Phase II Study of Weekly Topotecan With Bevacizumab in Platinum Resistant Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
PURPOSE: The purpose of this study is to evaluate the clinical safety and toxicity of intravenous bevacizumab (Days 1 and 15 of a 28 day cycle) in combination with weekly topotecan (Days 1, 8, 15 of a 28 day cycle) in patients with platinum resistant recurrent ovarian, fallopian tube and primary peritoneal cancer.
Phase II Trial of BIBW 2992 in Genetically Pre-screened Cancers with EGFR and/or HER2 Gene Amplification
PURPOSE: The primary objective of this trial is to estimate the objective response rate for patients with tumors harbouring EGFR and/or HER2 gene amplifications or EGFR activating mutations who will be treated with BIBW 2992.
Sorafenib and Bevacizumab in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer That is Recurrent or Did Not Respond to Previous Treatment
PURPOSE: This phase II trial is studying how well giving sorafenib together with bevacizumab works in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cavity cancer that is recurrent or did not respond to previous treatment.
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
PURPOSE: This multi-institutional phase I/II clinical trial will test the tolerability and efficacy of the combination sorafenib and topotecan in patients with recurrent ovarian cancer, which is platinum-resistant (recurrence within 6 months from completing platinum based therapy) or refractory (progressive disease during platinum based therapy).
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
PURPOSE: This randomized phase II trial is studying how well giving sorafenib together with paclitaxel and carboplatin works in treating patients with recurrent ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
PURPOSE: This study will determine the value of adding AMG 479 (fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with optimally debulked (<1 cm) FIGO stage III and IV (positive pleural cytology only) ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma
PURPOSE: The purpose of the study is to determine whether the combination of aflibercept, pemetrexed and cisplatin is safe and effective.
Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
PURPOSE: to obtain an estimate of the objective response rate (ORR) of AMG 479 in patients with recurrent platinum-sensitive ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma failing frontline chemotherapy.
Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer
PURPOSE: The purpose of this study is to test the effectiveness, safety and tolerability of the drug combination: gemcitabine, carboplatin and bevacizumab in patients that have been diagnosed with platinum sensitive recurrent ovarian cancer, fallopian tube or primary peritoneal cancer.
A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
PURPOSE: The purpose of this study is to evaluate the response rate (Complete Response (CR) and Partial Response (PR)) to carboplatin and DOXIL treatment in combination with bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube and primary peritoneal cancers. All patients will received DOXIL, carboplatin and bevacizumab for a maximum of ten 28-day cycles. Patients will be followed for six months following treatment to assess progression-free survival.
A Study of GDC-0449 (Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
PURPOSE: The proposed study is a Phase II, randomized, placebo-controlled, double-blind, multicenter clinical trial of GDC-0449 in patients with ovarian cancer in a second or third complete remission. Patients will be randomized in a 1:1 ratio to either GDC-0449 or placebo. Randomization will be stratified based on whether their cancer is in a second or third complete remission.
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
PURPOSE: The purpose of this study is to determine whether the investigational drug catumaxomab is a safe and effective treatment for recurrent symptomatic malignant ascites.
Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
PURPOSE: This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients with metastatic or locally advanced platinum-resistant ovarian cancer. Patients will be randomized 1:1 into one of two treatment arms. NKTR-102 will be administered at a dose level of 145 mg/m2 in both arms. In Arm A, NKTR-102 will be given on a q14d schedule. In Arm B, NKTR-102 will be given on a q21d schedule. Approximately 70 patients may be evaluated in this study with approximately 35 patients in each treatment arm.
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
PURPOSE: The purpose of this study is to determine the effectiveness of sunitinib on participants with ovarian, fallopian tube or peritoneal cancer. Sunitinib is a newly discovered drug that may stop cancer cells from growing by blocking the blood supply to the tumor.
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
PUPOSE: The purpose of this study is to determine if the combination of bevacizumab and pemetrexed have an effect on recurrent ovarian and primary peritoneal carcinoma by looking at progression and survival at 6 months.
VEGF Trap in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
PURPOSE: This phase II trial is studying how well VEGF Trap works in treating patients with locally advanced, unresectable or metastatic gynecologic soft tissue sarcoma.
Phase 1 trials:
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
PURPOSE: This phase I trial is studying the side effects and best dose of intraperitoneal infusions of carboplatin when given together with intravenous infusions of either docetaxel or paclitaxel followed by intraperitoneal paclitaxel in treating patients with stage II, stage III, or stage IV ovarian epithelial, fallopian tube, or primary peritoneal cavity carcinoma (cancer).
Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
PURPOSE: This phase I trial is studying the side effects and best dose of ABT-888 when given together with carboplatin, paclitaxel, and bevacizumab in treating patients with newly diagnosed stage II, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
PURPOSE: Comparison of Nexavar with a placebo as maintenance therapy for patients with advanced Ovarian or primary Peritoneal cancers in complete remission following surgery and one regimen of chemotherapy.
Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery
PURPOSE: This phase I trial is studying the side effects and best dose of dasatinib given together with bevacizumab in treating patients with solid tumor that is metastatic or cannot be removed by surgery.
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
PURPOSE: This phase I trial is studying the side effects and best dose of adjuvant intraperitoneal carboplatin when given together with paclitaxel and bevacizumab in treating patients who have undergone debulking surgery for stage II, stage III, or stage IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.
Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor
PURPOSE: This phase II trial is studying the side effects of giving temsirolimus together with bevacizumab and to see how well it works in treating patients with locally advanced, recurrent, metastatic, or progressive endometrial cancer, ovarian epithelial cancer, liver cancer, islet cell cancer, or carcinoid tumor.